calibrate

In this episode, Darcey Wooten, MD, discusses the long-acting HIV treatment agent lenacapavir for treatment-experienced people with HIV, including:

• Efficacy data
• Initiation strategies
• Virologic failure data
• Safety information

Presenter:

Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California

To download the slides:
http://bit.ly/3Jb1ofX

To view the full online program:
https://bit.ly/3ZjSFhg

In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including: 

• Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)
• Risk factors for virologic failure of LA CAB + RPV
• The ATLAS-2M study
• Combined clinical trials of LA CAB + RPV
• Practical considerations for LA CAB + RPV
• Implementation of LA CAB + RPV 
• Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension study
• Supporting candidates for LA antiretroviral therapy (ART)
• Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San Francisco
• Future LA ART 
• The investigational LA HIV capsid inhibitor lenacapavir (LEN)
• LEN resistance from the CAPELLA and CALIBRATE studies
• LEN injection-site reactions in the CAPELLA and CALIBRATE studies

Presenter: 

Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Link to full program:
https://bit.ly/3VIsDTg

Follow along with the slides at:
http://bit.ly/3Gh9AKG

In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses new HIV data from AIDS 2022, including:

• Prevention strategies
• Oral therapies
• LA therapies
• Cure
• COVID-19 in PWH

Faculty
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Follow along with the slides at
bit.ly/3SLuhBq

What does being uncomfortable REALLY mean?

Are you ready to play bigger, or are you ready to rest?

Are you sabotaging yourself if you continue to stretch, or is it the right thing for you to do?

I know, boo. I've experienced the confusion. 

Let's talk about it.

email: hello@shawnakathleen.com

Find All Things Here!

In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss novel therapies for HIV prevention and treatment, including: 

• Prevention
  • Cabotegravir for pre-exposure prophylaxis (PrEP) with the latest results from the HPTN 083 and HPTN 084 studies
  • Novel PrEP therapies in development, including islatravir and lenacapavir
• Initial therapy
  • Lenacapavir for initial therapy with results from the CALIBRATE study
• Switch strategies
  • Cabotegravir as a switch strategy with the latest results from the ATLAS-2M study, evaluating Q4W vs Q8W dosing, data on direct-to-inject without the oral lead-in, and data to date in pregnancy
• Heavily treatment–experienced patients
  • Currently available novel therapies for heavily treatment–experienced patients, including fostemsavir and ibalizumab
  • Lenacapavir for heavily treatment–experienced patients with results from the CAPELLA study

Presenters:

Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Reggio Emilia, Italy 

William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania 

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with the slides at:
https://bit.ly/3vWhjHj

Link to full program:
https://bit.ly/3fOl0XX

In this episode, Daniel R. Kuritzkes, MD, and David A. Wohl, MD, discuss new HIV data from CROI 2022, including:

• Prevention strategies
• LA therapies
• Second-line therapies
• The VISEND study comparing dolutegravir-based antiretroviral therapy (ART) vs protease inhibitor–based ART for second-line therapy
• The NADIA study comparing dolutegravir with darunavir/ritonavir and tenofovir disoproxil fumarate with zidovudine for second-line therapy
• Comorbidities and cure
• ACTG A5324 (InMIND) study of ART intensification for cognitive impairment in people with HIV
• IMPAACT P1107 case of patient with loss of HIV-1–specific antibody response and viral detection following CCR5∆32/∆32 cord/haploidentical transplant

Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

David A. Wohl, MD
Professor of Medicine
School of Medicine
Site Leader, Global Infectious Diseases Clinical Trials Unit
University of North Carolina at Chapel Hill

Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Follow along with an expanded slideset at:
https://bit.ly/3CItz0Z

Link to full program:
https://bit.ly/3tSpdAx

Hear insights from 3 faculty experts as they present emerging data and guidelines and engage in discussion on patient-centered ART selection for people with HIV.

Topics include assessing treatment options; individualizing ART for women of childbearing potential and during pregnancy, patients with OIs, and during the COVID-19 pandemic; and new data on investigational ART strategies. 

Learn how to:

• Apply the results of recent clinical studies and evolving treatment guidelines on the timing and choice of first-line ART and switch strategies and managing treatment-experienced patients with HIV
• Integrate individual patient factors such as drug–drug interactions, comorbidities, pregnancy status, adherence, and dosing preferences when selecting optimal ART
• Appropriately counsel patients regarding the anticipated clinical role of new and investigational ART regimens in individualized care

Presenters:
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Jean-Michel Molina, MD, PhD
Head of the Department of
Infectious Diseases
Saint-Louis Hospital, Assistance-Publique Hôpitaux de Paris
Professor of Infectious Diseases
University of Paris
Paris, France

Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics 
University Hospital
University of Modena and Reggio Emilia
Reggio Emilia, Italy

Follow along with the slides at: 
https://bit.ly/329c8ZP

See the entire program at:
https://bit.ly/3FkRofM

In this episode, Darcy Wooten, MD, discusses new HIV data from IDWeek 2021, including:

• A rapid test-and-treat program to start DTG/3TC in patients newly diagnosed with HIV (STAT)
• Efficacy when switching from 3-drug to 4-drug TAF-based regimens to DTG/3TC (TANGO)
• Virologic outcomes with 2-drug vs 3-drug ART regimens (Trio Health HIV Network Study)
• Metabolic complications in treatment-naive patients (Study 1489 and Study 1490)
• Resistance analysis of an investigational agent, lenacapavir (CALIBRATE)
• The Positive Perspectives Survey to evaluate the U=U Educational Campaign in North American patients

Presenter:

Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California

Link to full program:
https://bit.ly/3BCHF2E

In this second of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including data on investigational antiretroviral agents, lenacapavir and islatravir, and alternative dosing of BPaL for MDR-TB.  

This episode includes discussion of:

• An extension of FLAIR, demonstrating virologic efficacy and safety of long-acting CAB plus RPV at Week 124
• A Week 26 safety and efficacy analysis of CAPELLA, a study of lenacapavir in heavily treatment–experienced PWH
• CALIBRATE, a study of the safety and efficacy of lenacapavir in treatment-naive PWH
• A Week 96 safety analysis of Protocol 011, evaluating islatravir plus DOR in treatment-naive patients
• A Week 24 safety and pharmacokinetic analysis of Protocol 016, evaluating oral islatravir once monthly for PrEP
• ZeNix, a phase III trial of pretomanid, bedaquiline, and linezolid (BPaL) in patients with highly resistant TB

Presenters:

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Shobha Swaminathan, MD
Associate Professor
Division of Infectious Diseases  
Department of Medicine
Rutgers New Jersey Medical School
Newark, New Jersey

Follow along with the slides at:
https://bit.ly/3hvRN5b

Content based on an online CME program supported by an educational grant from ViiV Healthcare.

In this first of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive PWH.  

This episode includes discussion of:

• A Global Clinical Platform that evaluated outcomes of PWH hospitalized with COVID-19
• A post hoc analysis of TANGO, evaluating the virologic and metabolic outcomes when switching to DTG/3TC vs continued 3- or 4-drug TAF-based regimens
• A Week 48 analysis of SALSA, demonstrating virologic efficacy and favorable safety profile of switching to DTG/3TC vs continuing a 3-drug ART regimen

Presenters:

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Shobha Swaminathan, MD
Associate Professor
Division of Infectious Diseases  
Department of Medicine
Rutgers New Jersey Medical School
Newark, New Jersey

Follow along with the slides at:
https://bit.ly/3hvRN5b

Content based on an online CME program supported by an educational grant from ViiV Healthcare.

In this episode, Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, discuss key studies from IAS 2021 that will influence the role of the pharmacist in the treatment and prevention of HIV. Their discussion includes analyses of:

• The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TC
• The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TC
• An extension of the FLAIR study, evaluating efficacy and safety of long-acting CAB plus RPV in treatment-naive patients
• The CUSTOMIZE study, an implementation effectiveness study that evaluated the feasibility of implementing provision of long-acting CAB plus RPV in the clinic setting
• The HPTN 084 study of PrEP using CAB vs TDF plus FTC in sexually active cisgender women
• The CALIBRATE and CAPELLA studies of long-acting lenacapavir in treatment-naive and treatment-experienced patients, respectively

In addition, Drs. Cocohoba and Schafer discuss key considerations of these medications, including cost and acquisition logistics.

Presenters:

Jennifer Cocohoba, PharmD
Professor
Department of Clinical Pharmacy
University of California, San Francisco
San Francisco, California

Jason Schafer, PharmD
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Content based on conference coverage of IAS 2021 with educational rant support from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp.; and ViiV Healthcare.

Link to full program:
https://bit.ly/3z8SBnC

In this episode, Babafemi Taiwo, MBBS, discusses new HIV data from IAS 2021, including:

• WHO Global Clinical Platform: COVID-19 outcomes in PWH
• 2-drug regimen of DTG/3TC: efficacy, metabolic outcomes (TANGO)
• Investigational antiretroviral use
  • CAB LA + RPV LA in treatment-naive PWH (FLAIR)
• Investigational antiretroviral agents
  • LEN (CAPELLA, CALIBRATE)
  • ISL (P011, P016)
• Alternative BPaL dosing in treatment of drug-resistant TB (ZeNix)

Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP.; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Follow along with an expanded slideset at: 
https://bit.ly/3syWD5T

Link to full program: 
https://bit.ly/3z8SBnC

Joni Huffman brings her 15+ years of sales leadership to the conversation as we discuss what factors are important to calibrate on before an interview as well as some of the advantages and pitfalls to a team interview approach.  We also chat about Joni’s benchmarks for sales interviewees and what failures tell us about a candidate.